Xenetic Biosciences, Inc. And the University of Virginia Have Initiated a Research Agreement to Advance Their Oncology Platform Based on DNase Technology
Thursday, January 18, 2024
Xenetic Biosciences, Inc. (NASDAQ: XBIO) has disclosed a strategic collaboration with the University of Virginia (UVA) through the announcement of a Research Funding Agreement and a Material Transfer Agreement. This collaboration aims to propel the advancement of Xenetic's systemic DNase program.
The DNase-based oncology platform developed by Xenetic focuses on targeting neutrophil extracellular traps (NETs), intricate structures composed of extracellular chromatin coated with histones and other proteins. While NETs are typically expelled by activated neutrophils in response to microbial or pro-inflammatory challenges, the improper regulation of NETs can lead to inflammatory and autoimmune complications. In the context of cancer, it may also contribute to the creation of pro-tumorigenic environments, potentially hindering the efficacy of therapeutic interventions.
Under the terms of the agreements with UVA, Xenetic retains the option to secure an exclusive license for any new intellectual property resulting from the DNase research program. Overseeing the research conducted under this collaboration is Dr. Allan Tsung, a member of Xenetic's Scientific Advisory Board and Chair of the Department of Surgery at UVA School of Medicine. Dr. Tsung, an internationally recognized surgical oncologist and scientist, has conducted extensive research on the role of NETs in tumor development, metastasis, and resistance to existing cancer therapies.
Xenetic is actively progressing towards its planned first-in-human study, evaluating DNase in combination with immune checkpoint inhibitors or chemotherapy. The company believes that the data generated through this collaboration will be instrumental in fully realizing the potential of its DNase technology and providing insights for the clinical development of its lead solid tumor indications.
Jeffrey Eisenberg, CEO of Xenetic, is optimistic about the collaboration, stating that the agreements with UVA significantly enhance the company's development capabilities and resources. He believes that this collaboration will expedite development timelines. Furthermore, Eisenberg emphasizes the value of deepening the collaboration with Dr. Tsung, who has provided valuable perspectives and insights into Xenetic's DNase platform.
Dr. Tsung shares his enthusiasm for further exploring the potential of the DNase platform and working collaboratively with Xenetic to advance the program's development. He underscores a shared goal of evaluating DNase as a potential addition to available treatment options, especially in areas with significant unmet medical needs.
Source: xeneticbio.com
